Clinical Testing News and Research

RSS

Mast plans to develop vepoloxamer for chronic heart failure treatment

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.

23 Mar 2015

ISSCR statement calls for moratorium nuclear genome editing of human germ line

In a statement released yesterday, the International Society for Stem Cell Research called for a moratorium on attempts at clinical application of nuclear genome editing of the human germ line to enable more extensive scientific analysis of the potential risks of genome editing and broader public discussion of the societal and ethical implications.

23 Mar 2015

Weak spots in ebola’s defenses: an interview with Dr. Andrew Ward

There are hundreds of other antibodies against Ebola that we are in the process of imaging using the electron microscope. We are looking for new sites of vulnerability as well as subtle differences in the way the known sites are attacked. In particular we are looking for antibodies that the virus is unlikely to escape from when it mutates.

11 Mar 2015

Researchers develop improved MRI technique to provide effective treatment for prostate cancer

A research team including NIBIB-funded scientists has developed an improved MRI technique with the potential to provide more precise and effective treatment for prostate cancer. The imaging technique improves upon standard MRI to obtain clearer images of the extent of the tumor and its exact location. A sharper image can provide more accurate biopsies, enable better treatment planning, and help surgeons pinpoint the tumor while sparing surrounding healthy tissue.

10 Mar 2015

Africa's under-five children at greater risk of developing parasitic disease

Children under five living in sub-Saharan Africa are at greater risk than older children of developing a long-term parasitic disease, research suggests.

6 Mar 2015

Phthalate exposure in pregnancy adversely affects masculinization of male genitals in babies

Exposure to hormone-altering chemicals called phthalates - which are found in many plastics, foods and personal care products - early in pregnancy is associated with a disruption in an essential pregnancy hormone and adversely affects the masculinization of male genitals in the baby, according to research led by the University of Pittsburgh Graduate School of Public Health.

6 Mar 2015

Autism Speaks' affiliate DELSIA announces new funding for clinical trial of cognitive video game

Autism Speaks' not-for-profit affiliate Delivering Scientific Innovation for Autism has announced new funding for clinical testing of a cognitive video game designed to improve executive function skills in children and adolescents with autism.

3 Mar 2015

Agena releases MassARRAY 24-Well System for mass spectrometry-based genetic testing

Agena Bioscience today released the MassARRAY 24-Well System for mass spectrometry-based genetic analysis, adding to its existing MassARRAY portfolio. The new 24-well format is tailored to smaller clinical testing laboratories requiring modest sample throughput, reduced initial hardware costs, and reduced time to result.

24 Feb 2015

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application (CTA) to the German Competent Authority, the Paul-Ehrlich-Institut (PEI), requesting clearance to initiate a Phase 1 clinical trial investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin.

23 Feb 2015

TB Alliance announces initiation of first human trial of new TB drug candidate

TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354. It is the first new TB drug candidate to begin a Phase 1 clinical trial since 2009.

19 Feb 2015

Pelvalon receives FDA approval to market Eclipse System for improving bowel control in women

Pelvalon announced today that the U.S. Food and Drug Administration has granted the company's de novo request to market the Eclipse System, the first vaginal insert designed to provide bowel control, in the United States. Loss of bowel control, also known as fecal incontinence, is a condition that affects over 20 million women in the U.S.

14 Feb 2015

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Timing may be decisive when it comes to overcoming cancer's ability to evade treatment. By hitting breast cancer cells with a targeted therapeutic immediately after chemotherapy, researchers from Brigham and Women's Hospital (BWH) were able to target cancer cells during a transitional stage when they were most vulnerable, killing cells and shrinking tumors in the lab and in pre-clinical models.

12 Feb 2015

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.

11 Feb 2015

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

University of Chicago Medicine researchers have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has enabled them to identify small molecules that can inhibit adhesion and invasion, preventing ovarian cancers from spreading to nearby tissues.

10 Feb 2015

Two researchers receive Pioneer Award from Human Gene Therapy

Recognized for their pioneering work in the development of gene transfer technology using retroviral vectors to deliver therapeutic genes into cells, Richard C. Mulligan, PhD, Director of the Harvard Gene Therapy Initiative, Harvard Institutes of Medicine, Boston, MA, and A. Dusty Miller, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, received the Pioneer Award from Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

9 Feb 2015

Quest Diagnostics, CDC partner to identify trends in diagnosis and treatment for viral hepatitis

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis and treatment for four strains of viral hepatitis in the United States, based on insights revealed by analysis of Quest’s national testing database.

From Quest Diagnostics 29 Jan 2015

Quest Diagnostics, CDC collaborate to reduce deaths from hepatitis

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis and treatment for four strains of viral hepatitis in the United States, based on insights revealed by analysis of Quest's national testing database.

From Quest Diagnostics 28 Jan 2015

Clinical Testing News and Research

Mast plans to develop vepoloxamer for chronic heart failure treatment

ISSCR statement calls for moratorium nuclear genome editing of human germ line

Weak spots in ebola’s defenses: an interview with Dr. Andrew Ward

Researchers develop improved MRI technique to provide effective treatment for prostate cancer

Africa's under-five children at greater risk of developing parasitic disease

Phthalate exposure in pregnancy adversely affects masculinization of male genitals in babies

Autism Speaks' affiliate DELSIA announces new funding for clinical trial of cognitive video game

Agena releases MassARRAY 24-Well System for mass spectrometry-based genetic testing

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

TB Alliance announces initiation of first human trial of new TB drug candidate

Pelvalon receives FDA approval to market Eclipse System for improving bowel control in women

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

Two researchers receive Pioneer Award from Human Gene Therapy

Quest Diagnostics, CDC partner to identify trends in diagnosis and treatment for viral hepatitis

Quest Diagnostics, CDC collaborate to reduce deaths from hepatitis

Researchers explore KRAS pathway to find potential target for treating lung cancer

Efficacy of ebola vaccine to be assessed in large-scale clinical trial

UChicago researchers awarded NIH grants to develop novel medications for sleep apnea, asthma

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News